{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:04:03Z","timestamp":1787598243542,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.msard.2021.103143","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T12:25:20Z","timestamp":1625833520000},"page":"103143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"54","author":[{"given":"Bingxin","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangsuo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangjie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2021.103143_bib0001","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.msard.2021.103143_bib0002","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10072-007-0823-z","article-title":"Variable responses to rituximab treatment in neuromyelitis optica (Devic\u2019s disease)","volume":"28","author":"Capobianco","year":"2007","journal-title":"Neurol. Sci."},{"issue":"5","key":"10.1016\/j.msard.2021.103143_bib0003","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nri1838","article-title":"B-cell targeting in rheumatoid arthritis and other autoimmune diseases","volume":"6","author":"Edwards","year":"2006","journal-title":"Nat. Rev. Immunol."},{"issue":"25","key":"10.1016\/j.msard.2021.103143_bib0004","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2021.103143_bib0005","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/annonc\/mdf155","article-title":"Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study","volume":"13","author":"Igarashi","year":"2002","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.msard.2021.103143_bib0006","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Primer."},{"issue":"9","key":"10.1016\/j.msard.2021.103143_bib0007","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2021.103143_bib0008","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jns.2012.05.005","article-title":"Lack of response to rituximab therapy in patients with neuromyelitis optica: true non-responders or insufficient treatment?","volume":"319","author":"Kim","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2021.103143_bib0009","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1742-2094-8-146","article-title":"Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders","volume":"8","author":"Lehmann-Horn","year":"2011","journal-title":"J. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2021.103143_bib0010","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","article-title":"New therapies for neuromyelitis optica spectrum disorder","volume":"20","author":"Levy","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2021.103143_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.02.004","article-title":"Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder","volume":"317","author":"Lin","year":"2018","journal-title":"J. Neuroimmunol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2021.103143_bib0012","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2012.02.017","article-title":"Variable results after rituximab in neuromyelitis optica","volume":"317","author":"Lindsey","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2021.103143_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101933","article-title":"A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders","volume":"40","author":"Lu","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103143_bib0014","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.msard.2018.02.004","article-title":"Early relapse after RTX initiation in a patient with NMO\/MS overlap syndrome: how long to conclude to a failure treatment?","volume":"20","author":"Maillart","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103143_bib0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jneuroim.2015.11.006","article-title":"Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination","volume":"290","author":"Maurer","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"7","key":"10.1016\/j.msard.2021.103143_bib0016","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jocn.2010.12.011","article-title":"Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels","volume":"18","author":"Nakashima","year":"2011","journal-title":"J. Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.msard.2021.103143_bib0017","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1212\/NXI.0000000000000061","article-title":"Disease exacerbation after rituximab induction in neuromyelitis optica","volume":"2","author":"Perumal","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2021.103143_bib0018","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1352458515594042","article-title":"Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients","volume":"22","author":"Radaelli","year":"2016","journal-title":"Mult. Scler."},{"issue":"36","key":"10.1016\/j.msard.2021.103143_bib0019","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.2217\/fon-2019-0694","article-title":"20 years of rituximab treatment: what have we learnt?","volume":"15","author":"Renner","year":"2019","journal-title":"Fut. Oncol."},{"issue":"4","key":"10.1016\/j.msard.2021.103143_bib0020","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2021.103143_bib0021","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","article-title":"Rituximab in neurological disease: principles, evidence and practice","volume":"19","author":"Whittam","year":"2019","journal-title":"Pract. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.103143_bib0022","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2021.103143_bib0023","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821004107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821004107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:57:04Z","timestamp":1761901024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821004107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":23,"alternative-id":["S2211034821004107"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103143","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103143"}}